Skip to content

ARTERY SPIN LABELING COMBINED WITH DIFFUSION WEIGHTED IMAGING TO EARLY GUIDE ANTICOAGULATIVE THERAPY IN ISCHEMIC STROKE.

ARTERY SPIN LABELING COMBINED WITH DIFFUSION WEIGHTED IMAGING TO EARLY GUIDE ANTICOAGULATIVE THERAPY IN ISCHEMIC STROKE.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800018425
Enrollment
Unknown
Registered
2018-09-18
Start date
2019-01-01
Completion date
Unknown
Last updated
2018-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ISCHEMIC STROKE

Interventions

Group 2:Agathoban anticoagulation therapy
Group 1:Oral aspirin 100 mg once a day

Sponsors

Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18-80 years old; (2) Clinical diagnosis of acute ischemic stroke, 4.5 hours after onset or no thrombolysis, stroke after waking (unable to determine the time of onset); (3) Except for head CT monitoring Intracranial hemorrhage, no early large-area cerebral infarction images (deletion of sulci); (4) The National Institutes of Health Stroke Scale (NIHSS) score <25 points; (5) patient or family informed And signed an informed consent form.

Exclusion criteria

Exclusion criteria: (1) patients with intracranial hemorrhage and signs of subarachnoid hemorrhage; (2) patients with severe hypertension with systolic blood pressure =180 mmH or diastolic blood pressure =110 mmHg, or difficult to control after treatment; (3) brain Patients with epilepsy at the onset of stroke; (4) arterial puncture at the incompressible site in the last 7 days; (5) platelet count 22.2mmol/L, or difficult to control after treatment; (7) patients with severe heart, liver and kidney dysfunction; (8) with malignant tumors or ongoing anti-tumor treatment; (9) The magnetic resonance examination cannot be completed for various reasons; (10) The patient or family member knows and refuses to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
mRS;

Secondary

MeasureTime frame
30-day mortality;

Countries

China

Contacts

Public ContactLiu jiangyun

Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine

liujiangyun1984@163.com+86 18912979527

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026